Health Canada Approves First GLP-1 Weight Loss Pill as Daily Alternative to Injections

Health Canada has authorized a new weight loss medication that comes as a pill taken once a day, giving Canadians an alternative to weekly injections for the first time.

Foundayo, made by Eli Lilly, is approved for adults living with obesity and for adults who are overweight and have at least one related medical condition, such as high blood pressure or sleep apnea. The drug is also approved to help treat Type 2 diabetes.

A small molecule that survives the stomach

The active ingredient is orforglipron, a non-peptide GLP-1 receptor agonist. Because it is a smaller molecule than the peptide drugs used in current injections, it can be taken by mouth and absorbed without being broken down by the digestive system, said Dr. Ehud Ur, an endocrinologist in Vancouver who is not associated with Eli Lilly or Novo Nordisk.

“It seems to be just as good as if not better” for weight loss as semaglutide and tirzepatide, Ur said.

Who can take it, and when it arrives

Health Canada granted authorization on Nov. 13. Eli Lilly spokesperson Ethan Pigott said the company expects the capsules to be available in pharmacies in January.

For weight management, the approval covers people with a body mass index of 30 or higher, or 27 or higher with at least one weight related health condition. The starting dose is one milligram a day, rising in steps to a maximum of 36 milligrams a day. For weight management, the maintenance doses start at six milligrams.

One practical advantage is that the capsule can be taken with or without food. That sets it apart from Novo Nordisk’s Rybelsus, another GLP-1 pill already sold in Canada, which is approved only for Type 2 diabetes and must be taken on an empty stomach with a small amount of water, followed by a 30 minute wait before eating or drinking.

Side effects and what is still unknown

The most common side effects are gastrointestinal, including nausea, vomiting, diarrhea and constipation, and they are usually mild to moderate and most common while the dose is being increased. Less common risks include gallstones and, very rarely, pancreatitis.

The drug must not be used during pregnancy or while breastfeeding. Because orforglipron slows the emptying of the stomach, the birth control pill cannot be relied on for contraception while the dose is being increased, and another form of contraception is needed for 30 days after starting or raising the dose.

Ur said he is still waiting for clinical trial results on whether orforglipron protects the heart the way semaglutide and tirzepatide do. A cardiovascular outcome trial is under way, and the drug is also being studied for sleep apnea, osteoarthritis pain, high blood pressure and other conditions.

A second GLP-1 weight loss pill may soon follow. Novo Nordisk’s Wegovy pill is still awaiting Health Canada approval. Both Foundayo and the Wegovy pill are already approved and available in the United States.

Muhammad Amanullah

Owner and Administrator of The True Post. He oversees the organization’s management, editorial policies, and news standards while ensuring effective coverage of local and international news.

Related Articles

Back to top button